C4 therapeutics reports fourth quarter and full year 2024 financial results and recent business highlights

Planning activities are ongoing for next phase of cemsidomide clinical development in multiple myeloma and non-hodgkin's lymphoma; trials expected to initiate in early 2026

CCCC Ratings Summary

CCCC Quant Ranking